There are currently 61 active clinical trials seeking participants for COVID19 research studies. The states with the highest number of trials for Autism participants are Florida, Texas, California and New York.
Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development
NCT04956445
Recruiting
Collection of SARS-COV-2 Secretions and Serum for Countermeasure Development (aka ClinSeqSer) is an observational study to understand natural history of SARS-COV-2 infections among special populations and characterise post-covid morbidity through immune response, virus genome sequencing, cytokine response, and virus shedding. Given the descriptions of infection course of patients over the outbreak of 2003 (SARS-Cov01) and since January 2019 in China and Europe, and now worldwide: Acutely infect... Read More
Gender:
All
Ages:
Between 6 months and 120 years
Trial Updated:
12/20/2023
Locations: Tulane University Medical Center, New Orleans, Louisiana +1 locations
Conditions: Covid19
Register for Updates
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
NCT04910269
Recruiting
The primary objective of the Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) (INSIGHT 012) trial is to compare the safety and efficacy of a single infusion of anti-COVID-19 hyperimmune intravenous immunoglobulin (hIVIG) versus placebo among adults with recently diagnosed severe acute respiratory syndrome - coronavirus 2 (SARS-CoV2) infection who do not require hospitalization. The primary endpoint of this double-blind randomized trial is a five-category ordinal outcome that asse... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/19/2023
Locations: MedStar Health Research Institute, Washington, District of Columbia +37 locations
Conditions: COVID, SARS-CoV2 Infection, Covid19
Register for Updates
High Resolution Micro OCT Imaging
NCT03256773
Recruiting
The purpose of this study is to learn about using the imaging to make images of the lungs and nose with the long-term goal of the research leading to potential treatments and new therapies for patients with cystic fibrosis.
Gender:
All
Ages:
14 years and above
Trial Updated:
12/06/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Cystic Fibrosis, COPD, PCD - Primary Ciliary Dyskinesia, Covid19, Sinusitis
Register for Updates
COVID-19 Vaccines International Pregnancy Exposure Registry
NCT04705116
Recruiting
The objective of the COVID-19 Vaccines International Pregnancy Exposure Registry (C-VIPER) is to evaluate obstetric, neonatal, and infant outcomes among women vaccinated during pregnancy with a COVID-19 vaccine. Specifically, the C-VIPER will estimate the risk of obstetric outcomes (spontaneous abortion, antenatal bleeding, gestational diabetes, gestational hypertension, intrauterine growth restriction, postpartum hemorrhage, fetal distress, uterine rupture, placenta previa, chorioamnionitis, C... Read More
Gender:
Female
Ages:
Between 18 years and 50 years
Trial Updated:
11/14/2023
Locations: Pregistry, Los Angeles, California
Conditions: Covid19
Register for Updates
COVID-19 International Drug Pregnancy Registry
NCT05013632
Recruiting
The objective of the COVID-19 International Drug Pregnancy Registry (COVID-PR) is to evaluate obstetric, neonatal, and infant outcomes among women treated with monoclonal antibodies or antiviral drugs indicated for mild, moderate, or severe COVID-19 from the first day of the last menstrual period (LMP) to end of pregnancy. For monoclonal antibodies, the exposure period also includes 90 days prior to the first day of the LMP.
Gender:
Female
Ages:
Between 18 years and 50 years
Trial Updated:
11/14/2023
Locations: Pregistry, Los Angeles, California
Conditions: Covid19
Register for Updates
The Nanowear Wearable Covid-19 Observational and Analysis Trend
NCT04717024
Recruiting
The NanoCOAT study is a multi-center, prospective, non-randomized, feasibility, observational, non-significant risk study. The NanoCOAT study will enroll a minimum of 10 and a maximum of 100 subjects in a potential for a multi-site in order to collect data and analyze physiological and biometric trends due to Covid-19.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/07/2023
Locations: Hackensack University Medical Center, Hackensack, New Jersey +1 locations
Conditions: Covid19
Register for Updates
SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease
NCT04896606
Recruiting
The 2019 Severe Acute Respiratory Syndrome (SARS) is a global pandemic secondary to a novel coronavirus - SARS-CoV-2. The reported case-fatality ratio for SARS-CoV-2 in the United States is 1.8% with a current death toll of >300,000 and climbing.4 There is no accepted standard of care or FDA approved therapies for treatment of COVID-19. Virus specific cytotoxic T lymphocytes (CTLs) have become an important part of the treatment landscape for viral reactivation post hematopoietic and solid organ... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
10/24/2023
Locations: New York Medical College, Valhalla, New York +3 locations
Conditions: Covid19
Register for Updates
COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI)
NCT04818853
Recruiting
The purpose of this study is to identify the number of individuals with severe CoVID who require ventilator support and who develop serious fungal infections. The study is an observational study, meaning that we are not providing any intervention that does not involve usual standard of care. Our chief goal is to find evidence of fungal infection by using traditional, approved methods of diagnosis, but by applying these methods in the same way and frequency among all study participants. We will b... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/06/2023
Locations: The University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Covid19, Aspergillosis, Fungal Infection
Register for Updates
Imaging Immune Activation in COVID-19
NCT04815096
Recruiting
This is a single center, single arm exploratory imaging study involving up to two intravenous microdoses of [18F]F-AraG (the second tracer dose is optional) followed by whole-body PET-CT imaging in participants with convalescent COVID-19. Up to 20 participants will be enrolled over an accrual period of approximately 24 months. Each participant will undergo one PET-CT scan following 50 +/- 10 minutes uptake following a single bolus injection of [18F]F-AraG in order to determine the tissue distrib... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/27/2023
Locations: University of California, San Francisco, San Francisco, California
Conditions: Covid19, SARS-CoV Infection
Register for Updates
SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial
NCT04802408
Recruiting
Adults (aged 18-65 years) recently diagnosed with SARS-CoV-2 infection who use a 4-day combined intervention of nasal washes with 1% baby shampoo solution and oral gargles with Listerine Antiseptic® will have a reduced SARS-CoV-2 viral load compared to those using nasal and oral washes with normal saline. This combined intervention should be acceptable, tolerable and safe in this population. To test this, investigators are conducting a trial comparing the efficacy of a number of washes in reduci... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
09/06/2023
Locations: Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania +1 locations
Conditions: Covid19, SARS-CoV Infection
Register for Updates
Pilot Study for PET/MR Imaging of Covid-19
NCT04954248
Recruiting
The primary goal of this project is to study the feasibility of a prototype brain-dedicated PET insert for an MR scanner for simultaneous acquisition of PET/MR images of metabolism and perfusion in Covid-19 negative and positive/once positive subjects. This study serves as a pilot study for establishing an imaging protocol for combined PET and MR derived functional information as well as MRI acquired anatomical information.
Gender:
All
Ages:
21 years and above
Trial Updated:
08/19/2023
Locations: Stanford University, Palo Alto, California
Conditions: Brain Diseases, Covid19
Register for Updates
Comparative Effectiveness of Readmission Reduction Interventions for Individuals With Sepsis or Pneumonia
NCT04829188
Recruiting
An adaptive platform trial to compare effectiveness of different care models to prevent readmissions for patients hospitalized with sepsis or lower respiratory tract infection. The primary outcome is number of days spent at home within 90 days after hospital discharge.
Gender:
All
Ages:
21 years and above
Trial Updated:
07/26/2023
Locations: UPMC Presbyterian, Pittsburgh, Pennsylvania
Conditions: Sepsis, Pneumonia, Lower Resp Tract Infection, Covid19
Register for Updates